Spyre Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +142.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 12.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -14,510.6% | Better than 1% |
| Net margin | -38,238.1% | Better than 0% |
| Return on equity | -33.7% | Better than 12% |
| Return on invested capital | -39.1% | Better than 8% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -12.2% | Better than 45% |
| 6-month return | 26.2% | Better than 87% |
| 12-month return (ex latest month) | 272.3% | Better than 99% |
| Distance below 52-week high | 15.5% | Better than 70% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 13.3x | Better than 96% |
| Debt to assets | 6.5% | Better than 76% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 32.0% | Better than 51% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 97.63
- Open
- 95.93
- Day range
- 93.22 - 99.56
- Avg price
- 94.65
- Volume
- 805.36K
- Turnover
- 76.23M
- Turnover ratei
- 0.87%
- Volume ratioi
- 0.86
- Amplitudei
- 6.49%
- 52-week rangei
- 24.58 - 110.64
Valuation
- P/Ei
- -47.21
- P/E (TTM)i
- -33.62
- P/Bi
- 9.81
- EPSi
- -1.98
- Book value / shi
- 9.53
- Net profit
- -188.04M
- Net assets
- 905.15M
Share structure
- Market cap
- 8.88B
- Float capi
- 8.65B
- Shares out
- 94.97M
- Float sharesi
- 92.51M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
15.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-18.44M net over the window
Short interest
- Shares short
- 11.62M
- % of floati
- 12.60%
- Days to coveri
- 12.69
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Spyre Therapeutics (SYRE)?
Spyre Therapeutics last traded at 93.47. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Spyre Therapeutics's market cap?
About 8.88B.
What is the P/E ratio of Spyre Therapeutics?
The trailing twelve-month P/E is -33.62. The Valuation tab shows it against the stock's own five-year range.
Does Spyre Therapeutics pay a dividend?
Spyre Therapeutics does not currently pay a regular dividend.
Is Spyre Therapeutics a buy according to analysts?
The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 123.38, which implies 32.0% upside from the current price. This is not investment advice.
What is Spyre Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Spyre Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Spyre Therapeutics discussion 0 comments